Professional Advisory Services Inc decreased Procter & Gamble (PG) stake by 17.38% reported in 2018Q3 SEC filing. Professional Advisory Services Inc sold 33,227 shares as Procter & Gamble (PG)’s stock rose 12.93%. The Professional Advisory Services Inc holds 157,971 shares with $13.15M value, down from 191,198 last quarter. Procter & Gamble now has $248.26B valuation. The stock decreased 0.02% or $0.02 during the last trading session, reaching $99.24. About 11.59 million shares traded or 8.83% up from the average. The Procter & Gamble Company (NYSE:PG) has risen 3.25% since February 14, 2018 and is uptrending. It has outperformed by 3.25% the S&P500. Some Historical PG News: 29/05/2018 – PLUG POWER – FORKLIFT OPERATOR AT PROCTER & GAMBLE PLANT WAS INVOLVED IN AN ACCIDENT AND PASSED AWAY ON MAY 24TH; 19/04/2018 – P&G BUYS MERCK’S CONSUMER HEALTH BUSINESS FOR APPROX. EU3.4B; 13/03/2018 – Procter & Gamble: Ranir Acquires Rights to Patents Under Confidential Terms; 10/04/2018 – India Tissue & Hygiene Market 2018-2023 – Procter & Gamble Home Products Account for Around 55% of the Market Share – ResearchAndMarkets.com; 19/04/2018 – Moody’s Affirms Procter & Gamble’s Aa3 Rating Following Announced Acquisition Of Merck’s Consumer Health Business; Outlook Stable; 19/04/2018 – P&G Deal for Merck KGaA Business Valuation Is About EUR3.4B; 18/04/2018 – P&G Also Held Discussions With Pfizer Over Its Consumer Health Unit; 23/05/2018 – PROCTER & GAMBLE REPORTS PRICING OF DEBT TENDER OFFER; 06/03/2018 – ShieldX Builds Recognition for Its Unmatched Multi-Cloud Security Solution in the 14th Annual Info Security PG’s 2018 Global; 24/05/2018 – INTERVIEW-PROCTER & GAMBLE TO INVEST AROUND $50 MLN IN ITS PRODUCTION FACILITIES IN RUSSIA IN 2018 – EXEC
Among 3 analysts covering FibroGen (NASDAQ:FGEN), 3 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. FibroGen had 3 analyst reports since October 15, 2018 according to SRatingsIntel. The rating was maintained by Leerink Swann on Monday, October 15 with “Outperform”. The stock of FibroGen, Inc. (NASDAQ:FGEN) has “Buy” rating given on Wednesday, December 19 by Citigroup. As per Monday, February 11, the company rating was maintained by Stifel Nicolaus. See FibroGen, Inc. (NASDAQ:FGEN) latest ratings:
11/02/2019 Broker: Stifel Nicolaus Rating: Buy New Target: $71 Maintain
19/12/2018 Broker: Citigroup Old Rating: Neutral New Rating: Buy New Target: $71 Upgrade
15/10/2018 Broker: Leerink Swann Old Rating: Outperform New Rating: Outperform Old Target: $82 New Target: $84 Maintain
More notable recent FibroGen, Inc. (NASDAQ:FGEN) news were published by: Nasdaq.com which released: “Analysis: Positioning to Benefit within Motorola Solutions, FibroGen, UnitedHealth Group, Newell Brands, Vuzix, and Choice Hotels International — Research Highlights Growth, Revenue, and Consolidated Results – Nasdaq” on January 17, 2019, also Seekingalpha.com with their article: “Piper likes ChemoCentryx in premarket analyst action – Seeking Alpha” published on February 11, 2019, Nasdaq.com published: “First Week of FGEN February 15th Options Trading – Nasdaq” on January 07, 2019. More interesting news about FibroGen, Inc. (NASDAQ:FGEN) were released by: Seekingalpha.com and their article: “Catabasis Pharmaceuticals: My Long Thesis And Analysis – Seeking Alpha” published on January 15, 2019 as well as Nasdaq.com‘s news article titled: “FibroGen (FGEN) Reports Q3 Loss, Lags Revenue Estimates – Nasdaq” with publication date: November 08, 2018.
The stock decreased 0.90% or $0.52 during the last trading session, reaching $57.56. About 382,400 shares traded. FibroGen, Inc. (NASDAQ:FGEN) has declined 13.72% since February 14, 2018 and is downtrending. It has underperformed by 13.72% the S&P500. Some Historical FGEN News: 09/05/2018 – FIBROGEN 1Q LOSS/SHR 50C, EST. LOSS/SHR 51C; 21/05/2018 – FibroGen Presents Latest Data From PRAISE Phase 2b Study of Pamrevlumab in Idiopathic Pulmonary Fibrosis at American Thoracic; 18/04/2018 – The Andes Summit: More Than Ayahuasca – A Re-Validation of the Cultural Heritage of Ecuador’s Ancient Indigenous Wisdom; 12/04/2018 – ARGENTINA IS SAID TO PROBE TRADES OF ANDES FOR INSIDER TRADING; 31/05/2018 – ASTELLAS PHARMA INC – SAFETY PROFILE OF ROXADUSTAT WAS CONSISTENT WITH THAT OBSERVED IN PREVIOUS STUDIES BOTH IN DIALYSIS AND NON-DIALYSIS PATIENTS; 07/05/2018 – RESOURCE CAPITAL FUND Vl L.P. ANNOUNCES ACQUISITION OF UNITS IN LOS ANDES COPPER LTD; 13/03/2018 Announcing The First Andes Summit – Indigenous Wisdom-Keepers to Gather With People of The North to lnitiate a New Commitment to Earth Healing; 21/05/2018 – FIBROGEN: PAMREVLUMAB SLOWED IPF DISEASE PROGRESSION IN STUDY; 31/05/2018 – ASTELLAS PHARMA INC – FOURTH JAPAN PHASE 3 STUDY FOR ROXADUSTAT MET ITS PRIMARY ENDPOINT; 31/05/2018 – ASTELLAS PHARMA INC – ROXADUSTAT WAS WELL TOLERATED IN STUDY
FibroGen, Inc., a research-based biopharmaceutical company, discovers, develops, and commercializes therapeutic agents to treat serious unmet medical needs in the United States. The company has market cap of $4.89 billion. It is developing Roxadustat, an oral small molecule inhibitor of hypoxia inducible factor prolyl hydroxylases that is in Phase III clinical development for the treatment of anemia in chronic kidney disease; Pamrevlumab, a human-monoclonal antibody that inhibits the activity of connective tissue growth factor, which is in Phase II clinical development for the treatment of idiopathic pulmonary fibrosis, pancreatic cancer, liver fibrosis, and Duchenne muscular dystrophy; and FG-5200 for the treatment of corneal blindness resulting from partial thickness corneal damage. It currently has negative earnings. It has collaboration agreements with Astellas Pharma Inc. and AstraZeneca AB.
Investors sentiment increased to 0.79 in Q3 2018. Its up 0.01, from 0.78 in 2018Q2. It increased, as 37 investors sold PG shares while 756 reduced holdings. 139 funds opened positions while 490 raised stakes. 1.41 billion shares or 1.36% less from 1.43 billion shares in 2018Q2 were reported. 23,933 are owned by Great Lakes Advisors Ltd Liability Corporation. The United Kingdom-based Investec Asset Management has invested 0.15% in The Procter & Gamble Company (NYSE:PG). Davy Asset holds 1.6% of its portfolio in The Procter & Gamble Company (NYSE:PG) for 67,347 shares. Riverhead Capital Mgmt Limited Liability Com has invested 0.41% in The Procter & Gamble Company (NYSE:PG). Burns J W And Inc reported 72,157 shares stake. Taurus Asset Management Ltd Co accumulated 69,063 shares or 0.78% of the stock. 2.24M are held by Bahl & Gaynor. Tiedemann Ltd Llc has invested 0.06% in The Procter & Gamble Company (NYSE:PG). Moreover, Hyman Charles D has 1.41% invested in The Procter & Gamble Company (NYSE:PG). Tdam Usa holds 1.27% or 254,367 shares in its portfolio. Moreover, Convergence Invest Ltd Limited Liability Company has 0.37% invested in The Procter & Gamble Company (NYSE:PG) for 21,731 shares. Brandes Invest Prtn Limited Partnership invested in 49,200 shares. Rowland & Investment Counsel Adv owns 8,249 shares or 0% of their US portfolio. Cedar Rock Capital Ltd holds 12.93M shares. 639,944 were accumulated by State Of Alaska Department Of Revenue.
Since August 15, 2018, it had 0 buys, and 65 insider sales for $115.70 million activity. 9,000 shares were sold by Francisco Ma. Fatima, worth $891,000 on Tuesday, February 12. Shares for $348,872 were sold by Schomburger Jeffrey K on Wednesday, August 22. On Tuesday, November 13 Moeller Jon R sold $21.03M worth of The Procter & Gamble Company (NYSE:PG) or 228,905 shares. 19,049 shares valued at $1.81 million were sold by Grabowski Mary Theresa on Thursday, January 31. $418,112 worth of The Procter & Gamble Company (NYSE:PG) was sold by Bishop Steven D on Wednesday, August 22. Jejurikar Shailesh sold 3,410 shares worth $284,810. Fish Kathleen B had sold 599 shares worth $50,004 on Monday, August 27.